Hainan Honz Pharmaceutical Co - Asset Resilience Ratio

Latest as of June 2021: 0.27%

Hainan Honz Pharmaceutical Co (300086) has an Asset Resilience Ratio of 0.27% as of June 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Hainan Honz Pharmaceutical Co's working capital to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥7.01 Million

≈ $1.03 Million USD Cash + Short-term Investments

Total Assets

CN¥2.58 Billion

≈ $377.59 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2014–2019)

This chart shows how Hainan Honz Pharmaceutical Co's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 300086 asset base.

Liquid Assets Composition Over Time

This chart breaks down Hainan Honz Pharmaceutical Co's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read debt load of Hainan Honz Pharmaceutical Co for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥7.01 Million	0.27%
Total Liquid Assets	CN¥7.01 Million	0.27%

Asset Resilience Insights

Limited Liquidity: Hainan Honz Pharmaceutical Co maintains only 0.27% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Hainan Honz Pharmaceutical Co Industry Peers by Asset Resilience Ratio

Compare Hainan Honz Pharmaceutical Co's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Drug Manufacturers - Specialty & Generic	1.54%
Yunnan Baiyao Group Co Ltd SHE:000538	Drug Manufacturers - Specialty & Generic	8.38%
Guangdong Zhongsheng Pharmaceutical Co Ltd SHE:002317	Drug Manufacturers - Specialty & Generic	6.62%
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	Drug Manufacturers - Specialty & Generic	4.94%
Harbin Gloria Pharmaceuticals SHE:002437	Drug Manufacturers - Specialty & Generic	9.04%
Jiuzhitang Co Ltd SHE:000989	Drug Manufacturers - Specialty & Generic	7.86%
Renhe Pharmacy Co Ltd SHE:000650	Drug Manufacturers - Specialty & Generic	37.54%
Jiangsu Kanion Pharmaceutical Co Ltd SHG:600557	Drug Manufacturers - Specialty & Generic	0.29%

Annual Asset Resilience Ratio for Hainan Honz Pharmaceutical Co (2014–2019)

The table below shows the annual Asset Resilience Ratio data for Hainan Honz Pharmaceutical Co.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2019-12-31	0.94%	CN¥20.53 Million ≈ $3.00 Million	CN¥2.19 Billion ≈ $321.11 Million	+0.30pp
2017-12-31	0.63%	CN¥14.15 Million ≈ $2.07 Million	CN¥2.24 Billion ≈ $327.19 Million	-0.71pp
2016-12-31	1.34%	CN¥29.36 Million ≈ $4.30 Million	CN¥2.19 Billion ≈ $320.39 Million	-44.24pp
2015-12-31	45.58%	CN¥952.50 Million ≈ $139.38 Million	CN¥2.09 Billion ≈ $305.81 Million	+42.98pp
2014-12-31	2.59%	CN¥50.00 Million ≈ $7.32 Million	CN¥1.93 Billion ≈ $282.00 Million	--

pp = percentage points

About Hainan Honz Pharmaceutical Co

SHE:300086 China Drug Manufacturers - Specialty & Generic

Market Cap

$417.58 Million

CN¥2.85 Billion CNY

Market Cap Rank

#13294 Global

#3964 in China

Share Price

CN¥6.27

Change (1 day)

+0.16%

52-Week Range

CN¥5.63 - CN¥13.71

All Time High

CN¥17.75